Safety and Clinical Activity of MK-3475 as Initial Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

被引：6

作者：

Balmanoukian, A. S. ^{[1
]}

Rizvi, N. A. ^{[2
]}

Garon, E. B. ^{[3
]}

Patnaik, A. ^{[4
]}

Gandhi, L. ^{[5
]}

Leighl, N. B. ^{[6
]}

Goldman, J. W. ^{[7
]}

Eder, J. P. ^{[8
]}

Johnson, E. A. ^{[9
]}

Blumenschein, G. R. ^{[10
]}

Gubens, M. A. ^{[11
]}

Papadopoulos, K. P. ^{[4
]}

Lubiniecki, G. M. ^{[12
]}

Zhang, J. ^{[13
]}

Niewood, M. ^{[12
]}

Emancipator, K. ^{[14
]}

Dolled-Filhart, M. ^{[15
]}

Hanson, M. E. ^{[16
]}

Hui, R. ^{[17
]}

机构：

[1] Angeles Clin & Res Inst, Los Angeles, CA USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[3] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[4] South Texas Accelerated Res Therapeut, San Antonio, TX USA

[5] Dana Farber Canc Inst, Boston, MA 02115 USA

[6] Princess Margaret Canc Ctr UHN, Toronto, ON, Canada

[7] Univ Calif Los Angeles, Santa Monica, CA USA

[8] Yale Univ, New Haven, CT USA

[9] Mayo Clin Florida, Jacksonville, FL USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Univ Calif San Francisco, San Francisco, CA 94143 USA

[12] Merck & Co Inc, Whitehouse Stn, NJ USA

[13] Merck & Co Inc, Gwynedd, PA USA

[14] Merck Res Labs, Rahway, NJ USA

[15] Merck & Co Inc, Rahway, NJ 07065 USA

[16] Merck & Co Inc, Rahway, NJ 07065 USA

[17] Westmead Hosp, Sydney, NSW, Australia

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2014年 / 90卷

关键词：

D O I：

10.1016/j.ijrobp.2014.08.023

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S1 / S2

页数：2

共 50 条

[1] Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)
Rizvi, Naiyer A.
Garon, Edward B.
Patnaik, Amita
Gandhi, Leena
Leighl, Natasha B.
Balmanoukian, Ani Sarkis
Goldman, Jonathan Wade
Eder, Joseph Paul
Johnson, Elizabeth
Blumenschein, George R.
Gubens, Matthew A.
Papadopoulos, Kyriakos P.
Lubiniecki, Gregory M.
Zhang, Jin
Niewood, Michelle
Emancipator, Kenneth
Dolled-Filhart, Marisa
Hanson, Mary Elizabeth
Hui, Rina
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC).
Garon, Edward B.
Leighl, Natasha B.
Rizvi, Naiyer A.
Blumenschein, George R.
Balmanoukian, Ani Sarkis
Eder, Joseph Paul
Goldman, Jonathan Wade
Hui, Rina
Soria, Jean-Charles
Gangadhar, Tara C.
Sun, Jong-Mu
Patnaik, Amita
Gubens, Matthew A.
Lubiniecki, Gregory M.
Zhang, Jin
Niewood, Michelle
Emancipator, Kenneth
Dolled-Filhart, Marisa
Hanson, Mary Elizabeth
Gandhi, Leena
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[3] PRELIMINARY CLINICAL SAFETY AND ACTIVITY OF MK-3475 MONOTHERAPY FOR THE TREATMENT OF PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
Garon, Edward B.
Balmanoukian, Ani
Hamid, Omid
Hui, Rina
Gandhi, Leena
Leighl, Natasha
Gubens, Matthew A.
Goldman, Jonathan
Lubiniecki, Gregory M.
Lunceford, Jared
Gergich, Kevin
Rizvi, Naiyer
JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S364 - S365
[4] MK-3475 monotherapy for previously treated non-small cell lung cancer (NSCLC): Preliminary safety and clinical activity.
Garon, Edward B.
Balmanoukian, Ani
Hamid, Omid
Hui, Rina
Gandhi, Leena
Leighl, Natasha
Gubens, Matthew
Goldman, Jonathan W.
Lubiniecki, Gregory M.
Emancipator, Kenneth
Dolled-Filhart, Marisa
Lunceford, Jared
Gergich, Kevin
Rizvi, Naiyer A.
CLINICAL CANCER RESEARCH, 2014, 20
[5] Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001
Soria, J. C.
Flotten, O.
Horn, L.
Felip, E.
Gandhi, L.
Hui, R.
Hellmann, M.
Leighl, N.
Zhang, J.
Kondic, A.
Rangwala, R.
Lubiniecki, G. M.
Garon, E. B.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S726 - S727
[6] Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Besse, Benjamin
Vansteenkiste, Johan
Renault, Patrick-Aldo
Frimodt-Moller, Bente
Chao, Grace
Gil, Maciej
Barlesi, Fabrice
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1227 - S1228
[7] Development of a PD-L1 immunohistochemistry (IHC) assay for use as a companion diagnostic for pembrolizumab (MK-3475) in non-small cell lung cancer (NSCLC).
Dolled-Filhart, Marisa
Roach, Charlotte M.
Toland, Grant
Musser, Jeanette
Lubiniecki, Gregory M.
Ponto, Gary
Emancipator, Kenneth
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] MK-3475 (ANTI-PD-1 MONOCLONAL ANTIBODY) FOR NON-SMALL CELL LUNG CANCER (NSCLC): ANTITUMOR ACTIVITY AND ASSOCIATION WITH TUMOR PD-L1 EXPRESSION
Gandhi, Leena
Lubiniecki, Gregory
Balmanoukian, Ani
Hui, Rina
Hamid, Omid
Rizvi, Naiyer A.
Leighl, Natasha
Gubens, Matthew
Goldman, Jonathan W.
Emancipator, Kenneth
Dolled-Filhart, Marisa
Lunceford, Jared K.
Niewood, Michelle
Gergich, Kevin
Garon, Edward B.
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) : S154 - S154
[9] MK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): Antitumor activity and association with tumor PD-L1 expression
Gandhi, Leena
Balmanoukian, Ani
Hui, Rina
Hamid, Omid
Rizvi, Naiyer A.
Leighl, Natasha
Gubens, Matthew
Goldman, Jonathan W.
Lubiniecki, Gregory M.
Emancipator, Kenneth
Dolled-Filhart, Marisa
Lunceford, Jared K.
Niewood, Michelle
Gergich, Kevin
Garon, Edward B.
CANCER RESEARCH, 2014, 74 (19)
[10] Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.
Papadimitrakopoulou, Vassiliki
Patnaik, Amita
Borghaei, Hossein
Stevenson, James
Gandhi, Leena
Gubens, Matthew A.
Yang, James Chih-Hsin
Sequist, Lecia V.
Ge, Joy Yang
Bourque, Jennifer
Bachman, Robert D.
Im, Ellie
Gadgeel, Shirish M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →